Aster DM Health.

Aster DM Healthcare is in the final stages of merging with Blackstone-backed Quality Care India Limited (QCIL), which includes CARE Hospitals and KIMSHEALTH. The merger received overwhelming shareholder approval with 99.99% votes in favor and is currently awaiting CCI and NCLT approvals. The combined entity will operate 38 hospitals with over 10,000 beds, positioning it as one of the top three hospital chains in India. Management expects the merger to drive significant synergies in procurement, corporate costs, and geographic reach across nine Indian states.

The company is executing a robust expansion plan to add approximately 1,700 beds by FY27, increasing total capacity to over 6,800 beds. Major brownfield projects are underway at Aster Medcity (950 beds total), Aster CMI (850 beds), and Aster Whitefield (500 beds). In the current year, 271 beds have already been added. Crucially, management stated that this ₹1,100 crore expansion will be funded through internal accruals and existing cash flows, maintaining a net-cash positive balance sheet without additional debt.

Operating EBITDA margins for the India business expanded to 19.5% in 9M FY25, up from 16.6% a year ago. This was driven by a 12% increase in ARPOB and a reduction in material costs (excluding wholesale pharmacy) to 20.7%. Mature hospitals (6+ years) are already operating at a 25% EBITDA margin with a 36% ROCE. Management has set a target to reach a consolidated margin of 21% by FY27, supported by the ramp-up of newer hospitals like Whitefield and the breakeven of the pharmacy business by Q4 FY26.

The Karnataka and Maharashtra cluster showed the strongest growth at 33% YoY, reaching ₹1,054 crore in 9M FY25, with margins improving to 23.2%. The Kerala cluster, while seeing slightly muted growth due to seasonal flu timing and MVT shifts, remains the largest contributor with ₹1,609 crore revenue and 23.7% margins. The company is intentionally shifting its case mix toward high-end specialties like Oncology (up 28%), Cardiac (up 16%), and Neuro (up 19%), which is driving ARPOB higher despite slightly increasing material costs.

Aster Labs has successfully turned around, achieving a positive EBITDA margin of 8% in 9M FY25 after breaking even in Q4 FY24. External (non-Aster) business now accounts for 28-30% of lab revenue, up from ~22% last year, with a target to grow this segment by 35-40% in the coming year. The pharmacy business, currently operating 203 retail stores, is undergoing a consolidation phase to limit cash burn and is expected to reach breakeven by the end of FY26.